Format

Send to

Choose Destination
J Exp Med. 2003 Jun 16;197(12):1721-30.

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Author information

1
Department of Pathology, Ohio State University Medical Center, Columbus, OH 43210, USA.

Abstract

B7H1 (PDL1) and B7DC (PDL2) are two new members of the B7 family that can interact with PD-1, a putative negative regulator for immune function. Recent studies have provided evidence for inhibitory functions of both members via PD-1. Meanwhile, compelling evidence exists for costimulatory function of both members. Here we demonstrate that expression of B7DC on the tumor cells promotes CD8 T cell-mediated rejection of tumor cells, at both the induction and effector phase of antitumor immunity. Moreover, B7DC binds to PD-1(-/-) cells and enhances T cell killing in a PD-1-independent mechanism. Our results demonstrate a novel pathway for B7DC to promote tumor immunity and may reconcile the apparently contradictory findings on the function of B7DC.

PMID:
12810690
PMCID:
PMC2193953
DOI:
10.1084/jem.20022089
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center